Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 10/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | CCR7 | P32248 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632002 | 0.82 | CXCR2 (0.44) | CXCR2CXCR1CCR7CCR6PIK3C3 | |
| SCHEMBL13075319 | 0.78 | CXCR2 (0.73) | CXCR2CXCR1 | |
| SCHEMBL23621373 | 0.76 | CXCR2 (0.56) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL23220275 | 0.73 | CXCR2 (0.48) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL23220272 | 0.73 | CXCR2 (0.50) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL31688238 | 0.73 | CCR6 (0.76) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL31531200 | 0.73 | CCR6 (0.46) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL19351483 | 0.68 | CXCR2 (0.53) | CXCR2CXCR1CCR6KMT2A | |
| SCHEMBL30631988 | 0.68 | PDGFRB (0.39) | CXCR2PIK3C3CCNT1CDK9 | |
| SCHEMBL3717820 | 0.67 | CXCR2 (0.63) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | CXCR2 13/4885CXCR1 16/4885CCR7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.